Intersect ENT Stock Forecast, Price & News

-0.31 (-1.90 %)
(As of 06/23/2021 02:32 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,726 shs
Average Volume186,220 shs
Market Capitalization$530.59 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

Intersect ENT logo

About Intersect ENT

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.66 out of 5 stars

Medical Sector

366th out of 2,105 stocks

Surgical & Medical Instruments Industry

35th out of 174 stocks

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

Is Intersect ENT a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT
or view top-rated stocks.

What stocks does MarketBeat like better than Intersect ENT?

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Intersect ENT

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) announced its earnings results on Monday, May, 10th. The medical equipment provider reported ($0.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.09. The medical equipment provider had revenue of $24.30 million for the quarter, compared to the consensus estimate of $23.54 million. Intersect ENT had a negative net margin of 87.96% and a negative trailing twelve-month return on equity of 91.97%. Intersect ENT's quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.54) EPS.
View Intersect ENT's earnings history

How has Intersect ENT's stock been impacted by Coronavirus (COVID-19)?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XENT shares have decreased by 25.1% and is now trading at $16.11.
View which stocks have been most impacted by COVID-19

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $117 million-121 million, compared to the consensus revenue estimate of $119.41 million.

What price target have analysts set for XENT?

7 Wall Street analysts have issued twelve-month price objectives for Intersect ENT's shares. Their forecasts range from $19.00 to $32.00. On average, they anticipate Intersect ENT's stock price to reach $25.00 in the next year. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for Intersect ENT
or view top-rated stocks among Wall Street analysts.

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:
  • Mr. Thomas A. West, Pres, CEO & Director (Age 57, Pay $908.97k)
  • Mr. Richard A. Meier, Exec. VP & CFO (Age 61, Pay $621.76k)
  • Ms. Christine R. Kowalski, Exec. VP & COO (Age 64, Pay $581.04k)
  • Mr. Patrick A. Broderick, Exec. VP, Gen. Counsel & Corp. Sec. (Age 62, Pay $138.46k)
  • Ms. Reyna M. Fernandez, Chief Human Resource Officer
  • Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 57)

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT CEO Thomas West on Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Intersect ENT's key competitors?

What other stocks do shareholders of Intersect ENT own?

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a number of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (11.37%), BlackRock Inc. (8.98%), First Light Asset Management LLC (6.15%), Great Point Partners LLC (4.02%), Rock Springs Capital Management LP (3.26%) and Neuberger Berman Group LLC (2.98%). Company insiders that own Intersect ENT stock include Richard A Meier, Robert H Binney, Jr and Thomas A West.
View institutional ownership trends for Intersect ENT

Which institutional investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Jennison Associates LLC, D. E. Shaw & Co. Inc., Neuberger Berman Group LLC, Bank of New York Mellon Corp, Northern Trust Corp, Nuveen Asset Management LLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Intersect ENT
or view top insider-selling stocks.

Which institutional investors are buying Intersect ENT stock?

XENT stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Artisan Partners Limited Partnership, Rock Springs Capital Management LP, Polar Asset Management Partners Inc., BlackRock Inc., Eversept Partners LP, Altium Capital Management LP, and Geode Capital Management LLC. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT
or or view top insider-buying stocks.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $16.11.

How much money does Intersect ENT make?

Intersect ENT has a market capitalization of $533.90 million and generates $80.55 million in revenue each year. The medical equipment provider earns $-72,320,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

How many employees does Intersect ENT have?

Intersect ENT employs 406 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is

Where are Intersect ENT's headquarters?

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.